advertisement

Cancer

18 February 2020

Bone marrow transplants less risky now

The declining risk faced by bone marrow transplant patients is due to a decrease in transplant-related complications.

The risks faced by US bone marrow transplant patients have dropped sharply, a new study shows.

While this type of transplant can be lifesaving for patients with blood cancers (such as leukaemia) and other diseases, there are potentially life-threatening risks, the researchers noted.

Decrease in complications

But the new analysis of 1 148 patients who had bone marrow transplants at the Seattle Cancer Care Alliance between 2003 and 2007, and 1 131 patients who had the procedure between 2013 and 2017, showed a significant decline in risk.

Compared to the 2003–2007 group, the overall risk of death after transplant was 34% lower in the 2013–2017 group, even though they were older and sicker when they had their transplant, the findings showed.

The death rate among patients who had transplants between 2013 and 2017 was 40%, according to the report.

The declining risk is due to a decrease in transplant-related complications, said study corresponding author Dr George McDonald, an emeritus member at Fred Hutchinson Cancer Research Center, in Seattle.

The risk of bone marrow transplant patients dying from complications such as infections and diseases involving the liver, kidneys and lungs declined from 30% to 11% over the past 25 years.

Retrospective analysis

There was also a decrease in the risk of death from cancer relapse, which remains a major challenge, McDonald said.

The study was published in the Annals of Internal Medicine.

"Each of us has been working hard, trying to make our little corner of the problem less severe," McDonald said in a Hutchinson news release. "Cumulatively, those little improvements sum up to big improvements in outcomes. This paper reflects 25 years' worth of clinical research."

Because the study was a retrospective analysis, it can't pinpoint what's behind the improved patient outcomes. "But we can make really educated guesses as to why we're getting better," McDonald said.

The possible reasons include: improved methods to prevent, detect and treat infections that threaten transplant patients; pre-transplant identification of patients at high-risk for fatal complications; use of less-toxic chemotherapy and radiation regimens to prepare patients for transplant; advances in the prevention of graft-versus-host disease, where donor immune cells attack a patient's organs; lower doses of prednisone to treat graft-versus-host disease, which has led to fewer infections.

Image credit: iStock

 

Ask the Expert

Cancer expert

CANSA’s purpose is to lead the fight against cancer in South Africa. Its mission is to be the preferred non-profit organisation that enables research, educates the public and provides support to all people affected by cancer. Questions are answered by CANSA’s Head of Health Professor Michael Herbst. For more information, visit cansa.org.za.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules